Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists | Agenda Bookshop Skip to content
LAST CHANCE! Order items marked '10-20 working days' TODAY to get them in time for Christmas!
LAST CHANCE! Order items marked '10-20 working days' TODAY to get them in time for Christmas!
A01=Robert A. Copeland
Age Group_Uncategorized
Age Group_Uncategorized
Author_Robert A. Copeland
automatic-update
Category1=Non-Fiction
Category=MMG
Category=TDCW
COP=United States
Delivery_Delivery within 10-20 working days
Language_English
PA=Available
Price_€100 and above
PS=Active
softlaunch

Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists

English

By (author): Robert A. Copeland

Offers essential guidance for discovering and optimizing novel drug therapies

Using detailed examples, Evaluation of Enzyme Inhibitors in Drug Discovery equips researchers with the tools needed to apply the science of enzymology and biochemistry to the discovery, optimization, and preclinical development of drugs that work by inhibiting specific enzyme targets. Readers will applaud this book for its clear and practical presentations, including its expert advice on best practices to follow and pitfalls to avoid.

This Second Edition brings the book thoroughly up to date with the latest research findings and practices. Updates explore additional forms of enzyme inhibition and special treatments for enzymes that act on macromolecular substrates. Readers will also find new discussions detailing the development and application of the concept of drug-target residence time.

Evaluation of Enzyme Inhibitors in Drug Discovery begins by explaining why enzymes are such important drug targets and then examines enzyme reaction mechanisms. The book covers:

  • Reversible modes of inhibitor interactions with enzymes
  • Assay considerations for compound library screening
  • Lead optimization and structure-activity relationships for reversible inhibitors
  • Slow binding and tight binding inhibitors
  • Drug-target residence time
  • Irreversible enzyme inactivators

The book ends with a new chapter exploring the application of quantitative biochemical principles to the pharmacologic evaluation of drug candidates during lead optimization and preclinical development.

The Second Edition of Evaluation of Enzyme Inhibitors in Drug Discovery continues to offer a treatment of enzymology applied to drug discovery that is quantitative and mathematically rigorous. At the same time, the clear and simple presentations demystify the complex science of enzymology, making the book accessible to many fields— from pharmacology to medicinal chemistry to biophysics to clinical medicine.

See more
Current price €131.09
Original price €137.99
Save 5%
A01=Robert A. CopelandAge Group_UncategorizedAuthor_Robert A. Copelandautomatic-updateCategory1=Non-FictionCategory=MMGCategory=TDCWCOP=United StatesDelivery_Delivery within 10-20 working daysLanguage_EnglishPA=AvailablePrice_€100 and abovePS=Activesoftlaunch
Delivery/Collection within 10-20 working days
Product Details
  • Weight: 916g
  • Dimensions: 165 x 244mm
  • Publication Date: 16 Apr 2013
  • Publisher: John Wiley & Sons Inc
  • Publication City/Country: United States
  • Language: English
  • ISBN13: 9781118488133

About Robert A. Copeland

ROBERT A. COPELAND PhD is Executive Vice President and Chief Scientific Officer at Epizyme Inc. a biopharmaceutical company in Cambridge Massachusetts. He is on the Editorial Board of The Journal of Biological Chemistry and a member of the Faculty of 1000. Dr. Copeland has contributed more than 175 publications to the scientific literature and holds eight U.S.-issued patents. He has authored several books in protein science and enzymology including Enzymes: A Practical Introduction to Structure Mechanism and Data Analysis Second Edition (Wiley).

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)
We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept